5 Things Gilead's Q2 Earnings Numbers Didn't Tell You
Published: Aug 01, 2017
The numbers didn't lie: Gilead Sciences (NASDAQ:GILD) posted pretty good second-quarter results. While revenue and earnings fell compared to the prior-year period, the big biotech still managed to beat expectations thanks to strong HIV drug sales and a better-than-expected performance from its hepatitis C virus (HCV) franchise. Gilead even upped its full-year 2017 guidance.